Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JUNYA FUJIMOTO and IGNACIO IVAN WISTUBA.
JUNYA FUJIMOTO
Connection Strength
6.270
IGNACIO IVAN WISTUBA
  1. Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol. 2014 Jul; 31(4):306-13.
    View in: PubMed
    Score: 0.498
  2. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1747-1754.
    View in: PubMed
    Score: 0.448
  3. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Aug 01; 3(8):1051-1058.
    View in: PubMed
    Score: 0.155
  4. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Int J Cancer. 2017 10 15; 141(8):1589-1599.
    View in: PubMed
    Score: 0.154
  5. Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. Retrovirology. 2017 01 20; 14(1):3.
    View in: PubMed
    Score: 0.149
  6. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst. 2014 Mar; 106(3):dju004.
    View in: PubMed
    Score: 0.122
  7. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
    View in: PubMed
    Score: 0.122
  8. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.
    View in: PubMed
    Score: 0.121
  9. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013 Nov 15; 19(22):6261-71.
    View in: PubMed
    Score: 0.118
  10. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17.
    View in: PubMed
    Score: 0.111
  11. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr 15; 17(8):2434-43.
    View in: PubMed
    Score: 0.098
  12. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010 Feb 09; 5(2):e9112.
    View in: PubMed
    Score: 0.092
  13. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq. 2024 May 15.
    View in: PubMed
    Score: 0.062
  14. Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024 Apr; 628(8006):E1.
    View in: PubMed
    Score: 0.061
  15. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024 Mar; 627(8004):656-663.
    View in: PubMed
    Score: 0.061
  16. Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. Int J Mol Sci. 2024 Feb 16; 25(4).
    View in: PubMed
    Score: 0.061
  17. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study. J Thorac Oncol. 2023 Dec 07.
    View in: PubMed
    Score: 0.060
  18. Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images. Mod Pathol. 2024 Feb; 37(2):100398.
    View in: PubMed
    Score: 0.060
  19. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol. 2023 Dec; 36(12):100326.
    View in: PubMed
    Score: 0.059
  20. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.058
  21. Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma. Cancer Commun (Lond). 2023 08; 43(8):951-955.
    View in: PubMed
    Score: 0.058
  22. Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers. Front Oncol. 2023; 13:1025443.
    View in: PubMed
    Score: 0.057
  23. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.057
  24. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023 01 17; 133(2).
    View in: PubMed
    Score: 0.056
  25. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of?Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol. 2023 01; 36(1):100028.
    View in: PubMed
    Score: 0.056
  26. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov. 2022 11 02; 12(11):2626-2645.
    View in: PubMed
    Score: 0.056
  27. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer. 2022 10; 172:19-28.
    View in: PubMed
    Score: 0.055
  28. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform. 2022 07; 6:e2200040.
    View in: PubMed
    Score: 0.054
  29. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res. 2022 06 01; 28(11):2461-2473.
    View in: PubMed
    Score: 0.054
  30. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res. 2022 May 11; 41(1):172.
    View in: PubMed
    Score: 0.054
  31. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer. 2022 08; 127(3):569-576.
    View in: PubMed
    Score: 0.054
  32. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. J Natl Cancer Inst. 2022 02 07; 114(2):290-301.
    View in: PubMed
    Score: 0.053
  33. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.053
  34. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
    View in: PubMed
    Score: 0.052
  35. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.
    View in: PubMed
    Score: 0.052
  36. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer. 2021 11; 125(10):1333-1340.
    View in: PubMed
    Score: 0.051
  37. Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2021 May 12; 12(1):2888.
    View in: PubMed
    Score: 0.050
  38. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun. 2021 05 11; 12(1):2722.
    View in: PubMed
    Score: 0.050
  39. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov. 2021 10; 11(10):2506-2523.
    View in: PubMed
    Score: 0.050
  40. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel). 2021 Mar 12; 13(6).
    View in: PubMed
    Score: 0.050
  41. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol. 2021 03 09; 4(1):314.
    View in: PubMed
    Score: 0.050
  42. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.049
  43. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun. 2021 01 29; 12(1):687.
    View in: PubMed
    Score: 0.049
  44. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 03 08; 39(3):346-360.e7.
    View in: PubMed
    Score: 0.049
  45. Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med. 2021 01 01; 203(1):90-101.
    View in: PubMed
    Score: 0.049
  46. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020 11 04; 21(1):271.
    View in: PubMed
    Score: 0.048
  47. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1. Pathol Res Pract. 2020 Dec; 216(12):153267.
    View in: PubMed
    Score: 0.048
  48. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2021 01; 16(1):127-139.
    View in: PubMed
    Score: 0.048
  49. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):669-677.
    View in: PubMed
    Score: 0.048
  50. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.
    View in: PubMed
    Score: 0.048
  51. Molecular differences across invasive lung adenocarcinoma morphological subgroups. Transl Lung Cancer Res. 2020 Aug; 9(4):1029-1040.
    View in: PubMed
    Score: 0.048
  52. Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study. Chest. 2020 10; 158(4):1723-1733.
    View in: PubMed
    Score: 0.047
  53. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Ann Thorac Surg. 2020 10; 110(4):1131-1138.
    View in: PubMed
    Score: 0.047
  54. Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. J Thorac Dis. 2020 May; 12(5):1952-1959.
    View in: PubMed
    Score: 0.047
  55. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
    View in: PubMed
    Score: 0.047
  56. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
    View in: PubMed
    Score: 0.046
  57. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 04; 1:423-436.
    View in: PubMed
    Score: 0.046
  58. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol. 2020 05; 15(5):777-791.
    View in: PubMed
    Score: 0.046
  59. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.046
  60. Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. Cancer Res. 2020 05 15; 80(10):2056-2066.
    View in: PubMed
    Score: 0.046
  61. ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network. EBioMedicine. 2019 Dec; 50:103-110.
    View in: PubMed
    Score: 0.045
  62. Artificial Intelligence in Lung Cancer Pathology Image Analysis. Cancers (Basel). 2019 Oct 28; 11(11).
    View in: PubMed
    Score: 0.045
  63. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med. 2019 09 15; 200(6):742-750.
    View in: PubMed
    Score: 0.045
  64. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2019 07 05; 10(1):2978.
    View in: PubMed
    Score: 0.044
  65. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 09; 158(3):911-919.e6.
    View in: PubMed
    Score: 0.044
  66. Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study. Sci Rep. 2019 05 03; 9(1):6886.
    View in: PubMed
    Score: 0.044
  67. An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. Transl Oncol. 2019 Jun; 12(6):836-845.
    View in: PubMed
    Score: 0.043
  68. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 2019 Apr; 42:296-303.
    View in: PubMed
    Score: 0.043
  69. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661.
    View in: PubMed
    Score: 0.043
  70. Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Appl Immunohistochem Mol Morphol. 2019 02; 27(2):125-133.
    View in: PubMed
    Score: 0.043
  71. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 07 02; 128(7):3198.
    View in: PubMed
    Score: 0.041
  72. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018 08 10; 36(23):2386-2394.
    View in: PubMed
    Score: 0.041
  73. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 04 02; 128(4):1267-1282.
    View in: PubMed
    Score: 0.040
  74. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol. 2018 06; 31(6):947-955.
    View in: PubMed
    Score: 0.040
  75. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer. 2018 03; 117:73-79.
    View in: PubMed
    Score: 0.040
  76. Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. Cancer Prev Res (Phila). 2018 04; 11(4):237-248.
    View in: PubMed
    Score: 0.040
  77. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
    View in: PubMed
    Score: 0.040
  78. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 02; 13(2):246-257.
    View in: PubMed
    Score: 0.040
  79. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res. 2018 01 15; 24(2):341-350.
    View in: PubMed
    Score: 0.039
  80. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130.
    View in: PubMed
    Score: 0.039
  81. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget. 2017 Nov 10; 8(56):95466-95480.
    View in: PubMed
    Score: 0.039
  82. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017 Sep 26; 8(43):73419-73432.
    View in: PubMed
    Score: 0.039
  83. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
    View in: PubMed
    Score: 0.039
  84. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017 Apr 25; 8(17):28575-28587.
    View in: PubMed
    Score: 0.038
  85. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget. 2017 Mar 28; 8(13):21994-22002.
    View in: PubMed
    Score: 0.038
  86. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017 06; 30(6):826-833.
    View in: PubMed
    Score: 0.038
  87. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 2016 10 21; 7:13200.
    View in: PubMed
    Score: 0.037
  88. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases. Hum Pathol. 2017 01; 59:1-9.
    View in: PubMed
    Score: 0.036
  89. Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Res. 2016 07 01; 76(13):3676-83.
    View in: PubMed
    Score: 0.036
  90. Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. J Thorac Oncol. 2016 Mar; 11(3):346-360.
    View in: PubMed
    Score: 0.035
  91. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Sci Rep. 2015 Sep 07; 5:13846.
    View in: PubMed
    Score: 0.034
  92. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777.
    View in: PubMed
    Score: 0.033
  93. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Hum Pathol. 2015 Mar; 46(3):376-83.
    View in: PubMed
    Score: 0.032
  94. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9.
    View in: PubMed
    Score: 0.032
  95. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14788-93.
    View in: PubMed
    Score: 0.032
  96. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol. 2014 Dec; 45(12):2463-70.
    View in: PubMed
    Score: 0.032
  97. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul; 85(1):88-93.
    View in: PubMed
    Score: 0.031
  98. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3383-95.
    View in: PubMed
    Score: 0.029
  99. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811.
    View in: PubMed
    Score: 0.028
  100. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52.
    View in: PubMed
    Score: 0.027
  101. HER family receptor and ligand status in thymic carcinoma. Lung Cancer. 2012 Sep; 77(3):515-21.
    View in: PubMed
    Score: 0.027
  102. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.